Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia
- Conditions
- Bladder Cancer
- Registration Number
- NCT00491296
- Lead Sponsor
- HaEmek Medical Center, Israel
- Brief Summary
PURPOSE: We determined whether Synergo therapy- intravesical chemotherapy instillation combined with hyperthermia instillation is associated with elevated prostate specific antigen (PSA). MATERIALS AND METHODS: We will treat 25 consecutive patients with bladder cancer with a 6-week course of Synergo therapy, followed by cystoscopy at 6 weeks. Blood samples for PSA determination will obtain before each synergo therapy application and at cystoscopy with each patient also serving as a control.
Evaluating changes in PSA level in patients undergoing treatment with Synergo delivered local hyperthermia combined with intravesical instillation of Mitomycin C for adjuvant treatment or pt. with recurrent tu of bladder post TURT with BCGtreatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Male
- Target Recruitment
- Not specified
- Recurrent transitional cell carcinoma of urinary bladder post endoscopic resection
- PSA Prior synergo therapy application<10
- Normal rectal examination
- Patients willing to sign informed consent according
- History of prostate cancer
- Previous history of TCC stage T2 or higher
- Invasive tu of bladder
- Prior pelvic radiotherapy or systemic chemotherapy
- Active prostatitis
- Active tuberculosis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Haemek MC
🇮🇱Afula, Israel
Department of urology
🇮🇱Afula, Israel